Clearside Biomedical, Inc.
CLSD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $8 | $1 | $30 |
| % Growth | -79.8% | 519.9% | -95.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $8 | $1 | $30 |
| % Margin | 91% | 95.7% | 84.6% | 100% |
| R&D Expenses | $19 | $21 | $20 | $19 |
| G&A Expenses | $12 | $12 | $12 | $12 |
| SG&A Expenses | $12 | $12 | $12 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30 | $33 | $31 | $30 |
| Operating Income | -$29 | -$25 | -$30 | -$1 |
| % Margin | -1,735.7% | -302% | -2,281.6% | -2.1% |
| Other Income/Exp. Net | -$5 | -$8 | -$3 | $1 |
| Pre-Tax Income | -$34 | -$32 | -$33 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$34 | -$32 | -$33 | $0 |
| % Margin | -2,064.4% | -394.9% | -2,482.8% | 1.3% |
| EPS | -7.05 | -7.95 | -8.25 | 0.096 |
| % Growth | 11.3% | 3.6% | -8,693.8% | – |
| EPS Diluted | -7.05 | -7.95 | -8.25 | 0.095 |
| Weighted Avg Shares Out | 5 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 5 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $0 |
| Interest Expense | $10 | $9 | $3 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$24 | -$23 | -$29 | $1 |
| % Margin | -1,463.2% | -280.3% | -2,220.3% | 1.9% |